LEXICON PHARMACEUTICALS, INC. Cash and Cash Equivalents
LEXICON PHARMACEUTICALS, INC. (LXRX) had Cash and Cash Equivalents of $40.92 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $40.92M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $38.09M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $34.33M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $49.66M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $40.92M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $38.09M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $34.33M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $49.66M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $21.36M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $62.89M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $66.66M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $34.55M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $35.62M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $96.49M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $22.46M 10-K · filed 2025-03-07 | |
| 2023-09-30 | $21.12M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $102.27M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $26.00M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $46.34M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $18.83M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $21.45M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $59.52M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $64.06M 10-Q · filed 2023-05-04 | |
| 2021-09-30 | $92.12M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $89.89M 10-Q · filed 2022-08-03 | |
| 2021-03-31 | $97.65M 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $126.26M 10-K · filed 2023-03-03 | |
| 2020-09-30 | $52.25M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $86.94M 10-Q · filed 2021-08-06 | |
| 2020-03-31 | $55.59M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $36.11M 10-K · filed 2023-03-03 | |
| 2019-09-30 | $170.20M 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $11.11M 10-Q · filed 2020-07-29 | |
| 2019-03-31 | $45.78M 10-Q · filed 2020-04-27 | |
| 2018-12-31 | $80.39M 10-K · filed 2022-03-10 | |
| 2018-09-30 | $48.90M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $48.90M 10-Q · filed 2019-11-07 | $15.04M 10-Q · filed 2018-07-30 |
| 2018-03-31 | $20.42M 10-Q · filed 2019-05-01 | |
| 2017-12-31 | $61.66M 10-K · filed 2021-03-12 | |
| 2017-09-30 | $83.29M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $30.71M 10-Q · filed 2018-07-30 | |
| 2017-03-31 | $2.46M 10-Q · filed 2018-05-03 | |
| 2016-12-31 | $46.60M 10-K · filed 2020-03-12 | |
| 2016-09-30 | $38.77M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $38.41M 10-Q · filed 2017-08-01 | |
| 2016-03-31 | $24.68M 10-Q · filed 2017-05-04 | |
| 2015-12-31 | $202.99M 10-K · filed 2019-03-15 | |
| 2015-09-30 | $61.67M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $9.74M 10-Q · filed 2016-08-04 | |
| 2015-03-31 | $41.96M 10-Q · filed 2016-05-05 | |
| 2014-12-31 | $137.27M 10-K · filed 2018-03-01 | |
| 2014-09-30 | $26.77M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $27.73M 10-Q · filed 2015-08-07 | |
| 2014-03-31 | $46.52M 10-Q · filed 2015-05-05 | |
| 2013-12-31 | $37.50M 10-K · filed 2017-03-06 | |
| 2013-09-30 | $19.58M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | $23.25M 10-Q · filed 2014-08-07 | |
| 2013-03-31 | $34.25M 10-Q · filed 2014-05-08 | |
| 2012-12-31 | $30.42M 10-K · filed 2016-03-11 | |
| 2012-09-30 | $20.76M 10-Q · filed 2013-11-12 | |
| 2012-06-30 | $33.78M 10-Q · filed 2013-08-01 | |
| 2012-03-31 | $29.01M 10-Q · filed 2013-05-10 | |
| 2011-12-31 | $186.31M 10-K · filed 2015-03-12 | |
| 2011-09-30 | $30.52M 10-Q · filed 2012-11-07 | |
| 2011-06-30 | $20.33M 10-Q · filed 2012-08-02 | |
| 2011-03-31 | $20.12M 10-Q · filed 2012-05-03 | |
| 2010-12-31 | $47.21M 10-K · filed 2014-03-07 | |
| 2010-09-30 | $211.99M 10-Q · filed 2011-11-01 | |
| 2010-06-30 | $247.70M 10-Q · filed 2011-08-09 | |
| 2009-12-31 | $100.55M 10-K · filed 2013-03-11 | |
| 2008-12-31 | $85.87M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |